PDX Pharmaceuticals is an IND-enabling stage biotech developing nano-cancer immunotherapies. We aspire to substantially improve health care using our nanotechnology platforms. Of present focus are our patented AIRISE (Augmenting Immune Responses and Inhibiting the Suppressive Environment of Tumors) and ARAC (Antigen Release Agent and Checkpoint Inhibitor) pipelines that generate anti-tumor immunity when given locally (AIRISE) or systemically (ARAC) by relying on patient' s own tumor in situ as the source of antigens.